Commercialization & Market Access Advisory
Great science does not
guarantee market adoption.
Life Science Dx shapes commercialization strategy for diagnostics, precision medicine, life science tools, and healthcare technology companies — translating scientific promise into market access, workflow fit, clinical adoption, revenue growth, and strategic value.
Robert Carlson — Founder & Managing Director
Science creates possibility.
Strategy creates adoption.
Many life science and diagnostic companies are built around compelling technology, novel biomarkers, advanced platforms, or breakthrough scientific concepts. But strong science alone does not guarantee market adoption, reimbursement, physician engagement, or sustainable revenue.
Life Science Dx was created to help companies work through that transition. Founded by Robert Carlson — a diagnostics and life science commercial leader with more than 30 years of experience — the firm offers a practical, real-world perspective across diagnostic development, market access, and commercial execution.
Life Science Dx helps companies pressure-test the path from innovation to adoption — clarifying what evidence is needed, which stakeholders must see value, how the product fits into real-world workflows, and what commercial model can scale.
Practice Areas
Commercial Strategy Across the Diagnostics Lifecycle.
Authority & Credibility
A scientific-to-commercial perspective
across the diagnostics lifecycle.
Life Science Dx brings an operator-level perspective to diagnostic and precision medicine commercialization — combining scientific fluency, market access judgment, commercial execution, and corporate development experience.
That perspective allows Life Science Dx to evaluate diagnostics not only as technologies, but as businesses that must earn clinical trust, payer confidence, workflow adoption, sustainable revenue, and strategic value.
Scientific Foundation
Expertise across assay development, molecular diagnostics, companion diagnostics, NGS, AI-assisted interpretation, complex instrumentation, and clinical laboratory workflows.
Commercial Leadership
Launch readiness, positioning, sales model design, channel strategy, performance metrics, and customer-facing execution across physicians, health systems, IDNs, and national laboratories.
Executive Accountability
Revenue growth, P&L leadership, reimbursement, market access, commercial organization design, business development, partnerships, and strategic transactions.
End-to-End Diagnostics Perspective
Experience connecting science, evidence, workflow, reimbursement, commercial execution, partnerships, and corporate development.
Selected Experience
Life Science Dx Consulting draws on practical commercialization experience across diagnostics, precision medicine, AI-enabled healthcare, life science tools, companion diagnostics, specialty therapeutics, and clinical laboratory markets.
Selected client, advisory, and operating experience includes Prometheus Laboratories / Nestlé Health Science, Dako / Agilent Technologies, Biomerica, Owlstone Medical, Ibex Medical Analytics, Genece Health, Mithrl AI, Endpoint Health, Biacore, and Hybritech.
Real-world Diagnostics Strategy
Robert Carlson
Scientific Depth. Commercial Execution. Market Impact.
Robert Carlson has more than 30 years of combined scientific, commercial, business development, and operating leadership experience across diagnostics, life science tools, companion diagnostics, market access, and commercial execution.
Our Work
Questions that determine commercial readiness.
Life Science Dx supports companies facing questions such as:
- Is the market ready for this diagnostic or platform?
- Which customer segment should we prioritize first?
- How should we position the product for physicians, labs, payers, partners, or investors?
- What evidence is needed to support adoption and reimbursement?
- Which commercial model will scale?
- Where can partnerships accelerate growth?
Core Differentiation
Commercialization is not a late-stage activity.
It is an evidence strategy guided by commercial reality.
Successful diagnostics companies do more than prove that their technology works. They build the right evidence at the right time for multiple stakeholders — physicians, patients, payers, partners, investors, and commercial teams.
01
Scientific Validation
Does the biology work?
- Biomarker or signal biologically relevant?
- Intended analyte or signal measurable?
- Analytical performance benchmarked?
- Assay reproducible under controlled conditions?
02
Clinical Validation
Does the test perform in the intended clinical population?
- Intended-use population defined?
- Clinical association demonstrated?
- Comparator or standard method defined?
- Sensitivity and specificity support the clinical premise?
03
Clinical Utility
Does using the test change care?
- Clinical decision influenced?
- Patient management improved?
- Physician adoption supported?
- Payer and reimbursement evidence viable?
Commercial Strategy
Shapes which evidence is worth generating
Informs coding, reimbursement & payer strategy
Clarifies whether continued investment is justified
Life Science Dx Perspective
"The companies that win in diagnostics are the ones that treat commercial strategy as a scientific discipline — not an afterthought."
Robert Carlson · Life Science Dx
Insights & Perspectives
Scientific Progress Is Not Commercial Readiness.
A compelling diagnostic technology can still fail commercially if the evidence burden, coding and reimbursement pathway, workflow fit, and commercial execution plan are not clearly defined.
Featured Insight
Robert Carlson · May 2026
The Commercialization Gap in Diagnostics
Why strong science alone is not enough — and why diagnostics companies need clinical utility, market access strategy, workflow integration, and commercial discipline from the beginning.
How We Engage
Structured for your stage.
01
Project-Based
Defined scope
Focused engagements with clear deliverables — market assessments, launch readiness, reimbursement roadmaps, partnership support, or investor materials.
Start a conversation →
02
Strategic Advisory Retainer
Ongoing counsel
Monthly senior-level advisory support for leadership teams navigating commercialization, reimbursement, partnerships, product-market fit, or growth decisions.
Start a conversation →
03
Fractional Leadership
Part-time embedded leadership
Interim or fractional commercial leadership for companies that need senior expertise before adding, replacing, or committing to a full-time commercial executive.
Start a conversation →
Get in Touch
Have a diagnostic or life science innovation that needs a clearer commercial path?
Whether you are preparing for launch, refining your value proposition, building evidence for adoption, evaluating a partnership, or working through slower-than-expected commercial traction, Life Science Dx can help clarify the path forward.